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Fourteen patients with fibrolamellar hepatoma were 
treated with radical excision. In eight, a subtotal hepa-
tic resection was performed from 16 months to more 
than 76 years ago. N.one of the patients have died and 
recurrences have been seen in only one patient. Six 
other pat(ents h,ad total hepatectomy and hepatic re-
placement. Two of these six patients have died of me-
tastases and a third is living with recurrent tumor. 
This experience has justified the continuing use of 
quite aggressive extirpative procedures for the treat-
ment of fibrolamellar hepatoma. 
RECOGNITION of fibrolamellar hepatoma as a 
special pathologic entity dates from the descrip-
tion made by Edmondson in 1956 of a tumor sent 
to him by Brunschwig of New York (1). Further 
descriptions were written by one of Edmondson's 
associates, Peters (2). However, the clinical im-
portance of this hepatoma variant was not 
generally appreciated until 1980 when, in nearly 
simultaneous publications (3, 4), the emphasis 
was on the indolent growth often exhibited by 
such tumors and the good results that sometimes 
could be obtained with aggressive surgical ther-
apy. Because the material in these two series had 
been contributed on an individual patient by pa-
tient basis by many surgeons, the standards of 
management and the choices of operative pro-
cedures were variable. 
We present herein a series of 14 patients with 
fibrolamellar hepatoma treated during more than 
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16 years by a single group, namely the hepatic 
transplant team which was at the University of 
Colorado until December 1980 and subsequently 
at the University of Pittsburgh. Six resections 
were by total hepatectomy, followed by orthotopic 
hepatic transplantation. The other eight involved 
subtotal removal of the liver with right or left tri-
segmentectomy. By examining these instances, 
for which follow-up studies are available of 11 
months to almost 16 and one-half years, it has 
been possible to show what can be achieved with 
this disease using these two therapeutic options. 
METHODS 
University of Colorado series. Until late 1979, 
the surgeons and pathologists alike at the Uni-
versity of Colorado were unaware of the existence 
of fibrolamellar hepatomas or the clinical signif-
icance of this diagnosis. In November of that year, 
Doctors Shires and Popper of New York City 
called one of us about Patient No.3 in the Subto-
tal Resection Series, as given in Table I, who was 
being referred either for right trisegmentectomy 
or transplantation of the liver. Doctors Shires and 
Popper explained the favorable prognosis with 
the lesion and Doctor Popper described the 
characteristic histopathologic findings of eosi-
nophilic polygonal liver cells and interlacing 
bands of tightly packed collagen from which the 
descriptive term fibrolamellar derived. From that 
time onward, the question was frequently asked if 
specific patients from past experience had, in fact, 
had this kind of hepatoma, including a hepatic 
transplant recipient (Patient No. T2, Trans-
plantation Series) whose survival in spite of ex-
tremely adverse gross findings at operation far 
exceeded expectations. 
It remained for Farhi and associates in their 
exhaustive retrospective analysis of hepatomas in 
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young people at the University of Colorado (5) to 
clarify questions that had been unanswered at 
that institution for almost two decades. Ten (44 
per cent) of the 23 hepatomas seen in patients less 
than 35 years old between 1963 and 1981 had 
been of the fibrolamellar variety, including four 
treated on the general surgical service. The he-
patic transplantation team had treated the six 
other patients with partial hepatic resection 
(Patients No.1, 2, 3 and 4, Table I) or with total 
hepatectomy and orthotopic hepatic transplanta-
tion (Patients No. T1 and T2, Table I). 
University of Pittsburgh series. By 1981, the 
articles by Craig and Berman and their co-
workers had been published (3,4). There was no 
longer any ambiguity about the diagnosis of fi-
brolamellar hepatoma and all tumors of the liver 
were looked at by the pathologists with this 
diagnosis in mind. In the three years between 
January 1981 and December 1983, four fibro-
lamellar hepatomas were removed by partial 
hepatic resection. In addition, four complete 
livers containing fibrolamellar hepatomas were 
removed from patients who underwent orthotopic 
transplantation of the liver. 
Decisions about subtotal hepatectomy versus 
transplantation. Subtotal hepatectomy was con-
sidered the procedure of choice. If it was techni-
cally possible to encompass the tumor without 
devitalizing the residual hepatic remnant, this 
was done. The operation of right trisegmentec-
tomy which became a standardized procedure less 
than a decade ago (6) was used in six instances 
(Table I). The first reported left hepatic triseg-
mentectomy was used for a nine year old child 
(patient No.4) with a fibrolamellar hepatoma (7) 
and this same operation was used later for an 
adult (Patient No.8, Table I). In the early in-
stances, the sheer bulk of the tumors in those pa-
tients undergoing partial hepatectomy and the 
proximity of the lesions to portal triad structures 
or the major outflow veins made it difficult until 
the pathologic factors were later clarified to un-
derstand why the patients were alive and free of 
tumor many years later. 
Highly unfavorable conditions were also pres-
ent in four of the patients undergoing total hep-
atectomy and transplantation. In Patient No. T1, 
the tumor probably was cut through at the level of 
the suprahepatic vena caval cuff. In Patient No. 
T2, a tumor thrombus was found floating in the 
retrohepatic inferior vena cava. Its superior end 
was pulled back from the heart into the operating 
field. The portal vein was completely occluded by 
a tumor less than a centimeter from the site of 
transection in Patient No. T3. Patient No. T4, 
who had undergone a right trisegmentectomy 
four and one-half years earlier at another insti-
tution, had multiple metastases in the remaining 
lateral segment with invasion of the left dia-
phragm in the raw area encompassed by the left 
triangular ligament. Most of the left diaphragm 
was taken out with the specimen and replaced 
with Marlex mesh (polypropylene). 
Chemotherapy. Adjuvant chemotherapy with 
cyclosphosphamide, vincristine and actinomycin-
D was given prophylactically to Patient No.2 af-
ter partial hepatectomy. Patient No.5 was given 
the same drugs plus Adriamycin (doxorubicin 
hydrochloride) because a tumor was found at the 
site of parenchymal transection as well as the site 
of adhesions to the diaphragm. 
Because of pulmonary metastases, chemother-
apy with Adriamycin, 5-fluorouracil, mitomycin 
and vincristine was given to Patient No. T 4 15 
months after total hepatectomy and transplanta-
tion. Seven months later, the drug treatment was 
changed to dichloromethotrexate. 
RESULTS 
After partial hepatectomy. None of the seven 
patients with clean surgical margins and follow-
up periods of 11 months to more than 16 years 
have had a recurrence (Table I). Patient No.5 
with a tumor that was incompletely removed had 
slow growing recurrences within an eight month 
period. After three and one-half years, metastases 
in the celiac lymph nodes, on the thoracic and 
abdominal surfaces of the diaphragm and in the 
middle part of the mediastinum, were removed 
through separate abdominal and thoracic inci-
sions. No gross tumor was left behind. 
After replacement of the liver. Metastases from 
the fibrolamellar hepatomas were directly re-
sponsible for the deaths of two patients 14 and 
more than 32 months after transplantation. 
These recipients were not given chemotherapy. A 
third patient who underwent hepatic transplan-
tation (Patient No. T4) had already survived for 
four and one-half years after undergoing a right 
trisegmentectomy at another institution. She had 
pulmonary metastases develop one year after 
removal of the hepatic remnant and hepatic re-
placement. The pulmonary metastases have been 
moderately responsive to chemotherapy, and she 
remains in good condition 31 months after 
transplantation. 
The other three surviving transplant recipients 
have no obvious metastases after 12, 17 and 40 
months. However, it is far too soon to pronounce 
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TABLE I.-CLINICAL FEATURES 
Age, yrs., 
Patient race and Date of Extent of Time postresection Adjuvant therapy Survival 
No. sex resection resection to metastases postoperatively in months 
PARTIAL HEPATECTOMY 
1 20/W/F 7/20/68 Right trisegmentectomy None 196 
2 9/W/M 9/28/73 Right trisegmentectomy Multiple chemo. 134 
3 31/W/F 12/11/79 Right trisegmentectomy None 59 
4 9/W/M 6/13/80 Left trisegmentectomy None 53 
5 40/W/M 4/13/81 Right trisegmentectomy Tumor at margins Multiple chemo. 44 (Living with 
disease) 
6 14/W/M 2/03/83 Right trisegmentectomy None 21 
7 33/I/M 12/20/83 Right trisegmentectomy None 11 
8 40/W/M 12/30/83 Left trisegmentectomy None 11 
TRANSPLANTATION 
T1* 16/W/F 3/17/68 Total 12 Monthst None 14 (Died) 
(OT 14) 
T2 24/W/M 3/10/80 Total 30 Months* None PO~ (Died) 
(OT 172) 
T3 26/W/M 7/12/81 Total None 40 
(OT 194) 
T4 23/W/F 4/18/82 Total§ 13 Months Multiple chemo. 31 (Living with 
(OT 231) disease) 
T5 25/W/M 6/06/83 Total None 1T~ 
(OT300) 
T6 24/W/M 11/06/83 Total None 1O~ 
(OT 338) 
·OT, Orthotopic Transplantation; OT code numbers have been used in previous publications 
tMetastases proved at time of retransplantation. Death, two months later, was caused by a duodenal fistula. Metastases in diaphragm, retroperitoneal space 
and hepatic graft. 
*Extensive intraperitoneal seeding with "frozen" pelvis. No tumor in graft. 
§Right trisegmentectomy in December 1977. Hepatectomy completed with orthotopic transplantation four and one-half years later. Has multiple pulmonary 
metastases. 
I, Indian; W, white; F, female; M, male, and chemo., chemotherapy. 
them safe since the diagnosis of recurrence had 
been made from one to two and one-half years 
after transplantation (Table I). 
DISCUSSION 
The results in our experience with subtotal 
hepatic resections have verified the expectations 
of good survival reported by others (3, 4). It is 
noteworthy that not a single recurrence has been 
seen among the seven patients with lesions that 
could be removed completely with partial hepa-
tectomy. 
An eighth patient, with a tumor that was in-
completely removed, has survived for more than 
three and one-half years and has undergone late 
resection of metastases in the abdomen and chest. 
The presence of survivors for more than a decade 
after undergoing surgical treatment has provided 
retrospective justification for procedures which 
at the time were considered overly zealous by 
some. 
The less satisfactory behavior of patients Uil-
dergoing total hepatectomy and hepatic trans-
plantation was not surprising. By definition, such 
patients were rejects for partial hepatectomy by 
virtue of the more extensive disease. However, 
this may not be the only explanation for the 
poorer results. An additional adverse factor after 
hepatic transplantation has been performed may 
have been the necessity for continuous immuno-
suppression. 
More than 15 years ago, consequences of ia-
trogenic weakening of the immunologic surveil-
lance apparatus with immunosuppression were 
examined in several oncologic situations (8). The 
possible effects included: 1, an increased inci-
dence of de novo malignant conditions in patients 
without previous neoplasia; 2, a greater ability to 
transplant malignant cells which could become 
autonomous in a host which normally would re-
ject them, and 3, an augmentation or promotion 
of metastases which might otherwise have failed 
to become established. 
In the succeeding years, the evidence that im-
munosuppression can be influential in the first 
two of the aforementioned circumstances has been 
so overwhelming that it may be naive to believe 
that the same does not apply in the third. Even 
with the possibility that immunosuppression may 
have contributed to the growth of metastases, the 
meaningful prolongation of life that has been 
achieved by transplantation of the liver in those 
patients with fibrolamellar hepatoma and the fact 
that as many as one-half of the recipients may 
have been cured justify the continuing efforts 
at replacement of the liver for this type of lesion 
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as has been suggested in an earlier publication 
(9). 
SUMMARY 
Eight patients with fibrolamellar hepatoma 
were treated with subtotal hepatic resections from 
11 months to more than 16 years ago. Although 
the resections were at the extreme limits of tech-
nical feasibility, recurrences have been observed 
in one patient; none of the patients died. 
Six other patients with fibrolamellar hepato-
mas were treated with total hepatectomy and or-
thotopic transplantation of the liver. The inci-
dence of a recurrence of the tumor has been 50 
per cent and two of the six patients have died of 
metastases. 
The poorer incidence of tumor control may re-
flect the advanced nature of the lesions at surgical 
removal, an adverse effect of immunosuppression 
upon natural host defenses against malignant 
growths or a combination of both. Nevertheless, 
continued use of replacement of the liver to treat 
this hepatoma variant seems justified. 
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